celecoxib has been researched along with Helicobacter Infections in 19 studies
Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test whether the chronic users of celecoxib, a selective cyclo-oxygenase-2 inhibitor, had less Helicobacter pylori-related intestinal metaplasia or if such users' intestinal metaplasia could be prone to disappear after H." | 7.74 | Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. ( Cheng, HC; Hung, KH; Liou, MF; Sheu, BS; Wu, JJ; Yang, HB, 2007) |
| "Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| "To see whether celecoxib prevents gastric cancer occurrence by disrupting the progression of chronic gastritis into gastric carcinoma through its inhibition of the migration of CD133-positive cells, one of the surface markers of bone marrow-derived cells, in Helicobacter pylori-infected gerbils." | 3.76 | Celecoxib inhibits CD133-positive cell migration via reduction of CCR2 in Helicobacter pylori-infected Mongolian gerbils. ( Futagami, S; Gudis, K; Hamamoto, T; Horie, A; Kawagoe, T; Nagoya, H; Sakamoto, C; Shimpuku, M; Shindo, T, 2010) |
| "To test whether the chronic users of celecoxib, a selective cyclo-oxygenase-2 inhibitor, had less Helicobacter pylori-related intestinal metaplasia or if such users' intestinal metaplasia could be prone to disappear after H." | 3.74 | Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. ( Cheng, HC; Hung, KH; Liou, MF; Sheu, BS; Wu, JJ; Yang, HB, 2007) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| "Celecoxib (COX-2 inhibitor) inhibits gastric cancer cell proliferation, but with low treatment efficacy, limiting its applications." | 1.42 | Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study. ( Aziz, F; Wang, X; Yan, Q; Yang, X, 2015) |
| "pylori-induced gastric cancer cell motility and invasion." | 1.39 | Celecoxib inhibits Helicobacter pylori-induced invasion of gastric cancer cells through an adenine nucleotide translocator-dependent mechanism. ( Fan, L; Fang, D; Guo, GJ; Lan, C; Wan, S; Wang, J; Wang, R; Yang, L; Yang, S; Zhang, Y, 2013) |
| "Celecoxib treatment decreased the incidence of EA in rats undergoing EJA with H." | 1.37 | Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux. ( Gao, PP; Li, J; Liu, FX; Wang, J; Wang, WH, 2011) |
| "Celecoxib treatment significantly reduced MPO activity, TBARS levels and the incidence of gastric cancer." | 1.35 | Celecoxib inhibits apurinic/apyrimidinic endonuclease-1 expression and prevents gastric cancer in Helicobacter pylori-infected mongolian gerbils. ( Crowe, SE; Futagami, S; Gudis, K; Hamamoto, T; Horie, A; Kawagoe, T; Kusunoki, M; Miyake, K; Sakamoto, C; Shindo, T; Suzuki, K; Tsukui, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lan, C | 1 |
| Yang, L | 1 |
| Fan, L | 1 |
| Zhang, Y | 3 |
| Wang, J | 2 |
| Guo, GJ | 1 |
| Wan, S | 1 |
| Yang, S | 1 |
| Wang, R | 1 |
| Fang, D | 1 |
| Nakamura, M | 1 |
| Takahashi, T | 1 |
| Matsui, H | 1 |
| Takahashi, S | 1 |
| Murayama, SY | 1 |
| Suzuki, H | 1 |
| Tsuchimoto, K | 1 |
| Aziz, F | 1 |
| Yang, X | 1 |
| Wang, X | 1 |
| Yan, Q | 1 |
| Pan, KF | 3 |
| Zhang, L | 3 |
| Ma, JL | 3 |
| Zhou, T | 1 |
| Li, JY | 3 |
| Shen, L | 2 |
| You, WC | 3 |
| Zeng, HM | 1 |
| Nie, XR | 1 |
| Futagami, S | 3 |
| Kawagoe, T | 2 |
| Horie, A | 2 |
| Shindo, T | 3 |
| Hamamoto, T | 3 |
| Suzuki, K | 2 |
| Kusunoki, M | 2 |
| Miyake, K | 2 |
| Gudis, K | 3 |
| Tsukui, T | 2 |
| Crowe, SE | 1 |
| Sakamoto, C | 3 |
| Zhang, LJ | 1 |
| Wang, SY | 1 |
| Huo, XH | 1 |
| Zhu, ZL | 1 |
| Chu, JK | 1 |
| Ma, JC | 1 |
| Cui, DS | 1 |
| Gu, P | 1 |
| Zhao, ZR | 1 |
| Wang, MW | 1 |
| Yu, J | 1 |
| Hung, KH | 2 |
| Yang, HB | 3 |
| Cheng, HC | 3 |
| Wu, JJ | 2 |
| Sheu, BS | 3 |
| Shimpuku, M | 1 |
| Nagoya, H | 1 |
| Oshima, H | 1 |
| Hioki, K | 1 |
| Popivanova, BK | 1 |
| Oguma, K | 1 |
| Van Rooijen, N | 1 |
| Ishikawa, TO | 1 |
| Oshima, M | 1 |
| Liu, FX | 1 |
| Wang, WH | 1 |
| Li, J | 2 |
| Gao, PP | 1 |
| Wong, BC | 2 |
| Liu, WD | 1 |
| Feng, GS | 1 |
| Zhang, XD | 1 |
| Lu, AP | 1 |
| Xia, HH | 1 |
| Lam, S | 1 |
| Tsai, YC | 1 |
| Wu, CT | 1 |
| Chang, WL | 1 |
| Graham, DY | 1 |
| Lehmann, FS | 1 |
| Gyr, N | 1 |
| Lamarque, D | 1 |
| Lai, KC | 1 |
| Chu, KM | 1 |
| Hui, WM | 1 |
| Hu, WH | 1 |
| Wong, WM | 1 |
| Chan, AO | 1 |
| Wong, J | 1 |
| Lam, SK | 1 |
| Liou, MF | 1 |
| Hiratsuka, T | 1 |
| Tatsuguchi, A | 1 |
| Ueki, N | 1 |
| Shinji, Y | 1 |
| Wada, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis.[NCT05544396] | 100 participants (Anticipated) | Interventional | 2023-11-08 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for celecoxib and Helicobacter Infections
| Article | Year |
|---|---|
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin | 2003 |
7 trials available for celecoxib and Helicobacter Infections
| Article | Year |
|---|---|
Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; China; Clarithromycin; Cyclooxygenase 2; Cyclo | 2015 |
Alterations of Cyclooxygenase-2 Methylation Levels Before and After Intervention Trial to Prevent Gastric Cancer in a Chinese Population.
Topics: Adult; Anti-Bacterial Agents; Asian People; Celecoxib; Chromatography, High Pressure Liquid; Cycloox | 2016 |
Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.
Topics: Adult; Aged; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2009 |
Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradication.
Topics: Aged; Atrophy; beta Catenin; Biomarkers; Blood Urea Nitrogen; Celecoxib; Creatinine; Cyclooxygenase | 2010 |
Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; Clarithromycin; Cyclooxygenase 2 Inhibitors; D | 2012 |
Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia After H. pylori eradication.
Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Gastritis, Atrophic; Helicobacter Infections; | 2013 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
11 other studies available for celecoxib and Helicobacter Infections
| Article | Year |
|---|---|
Celecoxib inhibits Helicobacter pylori-induced invasion of gastric cancer cells through an adenine nucleotide translocator-dependent mechanism.
Topics: Anoikis; Celecoxib; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2 Inhibitors; | 2013 |
New pharmaceutical treatment of gastric MALT lymphoma: anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib.
Topics: Angiogenesis Inhibitors; Animals; Antibodies; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models | 2014 |
Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cycl | 2015 |
Celecoxib inhibits apurinic/apyrimidinic endonuclease-1 expression and prevents gastric cancer in Helicobacter pylori-infected mongolian gerbils.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Disease Progression; DNA-(Apurinic or Apyrimidinic Si | 2008 |
Celecoxib inhibits CD133-positive cell migration via reduction of CCR2 in Helicobacter pylori-infected Mongolian gerbils.
Topics: AC133 Antigen; Adenocarcinoma; Animals; Antigens, CD; Blotting, Western; Celecoxib; Cell Count; Cell | 2010 |
Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors.
Topics: Animals; Antibodies, Neutralizing; Benzamides; Celecoxib; Cell Line; Cell Transformation, Neoplastic | 2011 |
Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Barrett Esophagus; CDX2 Transcription Factor; Celeco | 2011 |
NSAIDs, Helicobacter pylori, and Pandora's Box.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Dyspepsia; Female; Gastric Mucosa; Helicobacter Infections; He | 2007 |
Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils.
Topics: Animals; Biomarkers, Tumor; Biopsy, Needle; CDX2 Transcription Factor; Celecoxib; Disease Models, An | 2006 |